At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
Smart insulin pens and CGM +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Improving Glycemic Control and Clinical Outcomes in DM2 Patients in the Ambulatory Setting, a Pilot Study
In Brief
A clinical study evaluating Smart insulin pens and CGM and Point of Care Glucose Group for Diabetes Mellitus. Completed, enrolled 30 participants across 1 site.
Detailed Summary
More than 10.5% of the US population has diabetes mellitus. The objective of this pilot study is to evaluate whether smart insulin pens combined with CGM devices can improve glucose control in patients with type 2 diabetes (T2D)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartAug 2021
Primary CompletionJul 2024
TodayJul 2026
First PostedMar 16, 2021
Enrollment StartAug 16, 2021
Primary CompletionJul 9, 2024
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 5.3 years ago
Interventions
Smart insulin pens and CGMdevice
Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices
Point of Care Glucose Groupother
Participants in this group will be monitored by POC glucose values.